

Form PTO-1390 (Rev. 01-2003)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER TAM-051
		TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. Not yet assigned 107519983
INTERNATIONAL APPLICATION NO. PCT/JP2003/008551	INTERNATIONAL FILING DATE July 2, 2003	PRIORITY DATE CLAIMED July 5, 2002	
TITLE OF INVENTION PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES		DATE January 4, 2005	
APPLICANT(S) FOR DO/EO/US Yasuhiro KAJIHARA			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). (90 pages). <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> a. PCT/ISA/210 b. PCT/ISA/220 c. PCT/IB/301 d. PCT/IB/304 e. PCT/IB/308 f. PCT/IB/332 g. PCT/IPEA/408 h. PCT/IPEA/409 i. PCT/IPEA/416 j. WO 2004/005330 A1 (cover page) 			

U.S. Application No. Not yet assigned 10/519983		International Application No. PCT/JP2003/008551		Attorney's Docket No. TAM-051
		CALCULATIONS	PTO USE ONLY	
21. [XX] The following fees are submitted:				
Basic National Stage Fee \$300.00 National Stage Search Fee \$500.00 National Stage Examination Fee \$200.00 TOTAL FEE FOR ENTERING U.S. NATIONAL STAGE = \$ 1,000.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				
National Stage Application Size Fee - If the specification and drawings exceed 100 sheets, the application size fee due is \$250.00 for each additional 50 sheets or fraction thereof.				
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	18 - 20		x \$ 50.00	\$ 0.00
Indep. claims	4 - 3	1	x \$ 200.00	\$ 200.00
Multiple dependent claim(s) (if applicable)			+ \$ 360.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS			=	\$ 1,200.00
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.			=	\$ 0.00
SUB TOTAL			=	\$ 1,200.00
Processing fee \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			=	\$ 0.00
TOTAL NATIONAL FEE			=	\$ 1,200.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			=	\$ 0.00
TOTAL FEES ENCLOSED			=	\$ 1,200.00
			Amount to be refunded:	\$
			charged	\$
a. [XX] Payment by credit card in the amount of <u>\$1,200.00</u> (Form PTO-2038 is enclosed).				
b. [] Please charge my Deposit Account No. <u>111833</u> in the amount of _____ to cover the above fees.				
c. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>111833</u> .				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to review (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: KUBOVCIK & KUBOVCIK The Farragut Building Suite 710 900 17th Street, N.W. Washington, D.C. 20006			 Signature Keiko Tanaka Kubovcik Name 40,428 Registration Number <u>January 4, 2005</u> Date	

KTK/jbf

P-001-05Wtam-091-pto-trn.wpd